Skip to main content

Table 2 Summary of characteristics and clinical endpoints of the Singapore trial evaluating the combination of chemotherapy and adoptive T-cell therapy in NPC

From: Comparative safety and efficacy of anti-PD-1 monotherapy, chemotherapy alone, and their combination therapy in advanced nasopharyngeal carcinoma: findings from recent advances in landmark trials

Items Singapore trial
 Phase 2
 Key eligibility criteria Treatment-naïve recurrent/metastatic EBV-positive NPC
 Experimental regimen Chemotherapy+EBV-CTLs: Gemcitabine 1000 mg/m2, and carboplatin (AUC 2) (days 1, 8 and 15) q4wks for 4 cycles, followed by EBV-CTL 1 × 108 cells/m2 on weeks 0, 2, 8, 16, 24, and 32
 Sample size 35
Clinical endpoints
 Median follow-up, months 29.9
 ORR (%) 71.5
 CR (%) 8.6
 PR (%) 62.9
 SD (%) 28.6
 PD (%) 0
 All grade AEs (%) NR
 Grade 3–5 AEs (%) NR
  1. Abbreviations: AUC area under the curve, CR complete response, EBV Epstein-Barr virus, EBV-CTLs EBV-specific cytotoxic T lymphocytes, NPC nasopharyngeal carcinoma, NR not reported, ORR objective response rate, q4wks every 4 weeks, PD progressive disease, PR partial response, SD stable disease